Balancing the Scales: The Complementary Roles of RCTs and RWE in Modern Healthcare
Christopher M. Gallagher, MD
RWE Where RCTs Fall Short: Optimizing Frontline Treatment of HR+/HER2- Metastatic Breast Cancer
Adam Brufsky, MD, PhD
Unlocking Insights for Underrepresented Patients: The Role of Real-World Evidence in Addressing Limitations of CDK4/6 Inhibitor RCTs
Distinguishing Between High- and Low-Quality RWE: A Journal Club for the Real World
Real World Evidence To Expand Knowledge of CDK4/6 Inhibitor-Related Adverse Effects
Importance of the Patient Perspective on RWE in Formulating SDM Conversations
Real World Use of RWE in HR+ Metastatic Breast Cancer: The Oncologist Perspective
RWE Supporting CDK4/6 Inhibitor Use in HR+ Metastatic Breast Cancer
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We’re glad to see you’re enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.